NewAmsterdam Pharma Company NAMS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's additional paid-in capital?
- NewAmsterdam Pharma Company (NAMS) reported additional paid-in capital of $1.46B in Q1 2026.
- How has NewAmsterdam Pharma Company's additional paid-in capital changed year-over-year?
- NewAmsterdam Pharma Company's additional paid-in capital increased by 7.4% year-over-year, from $1.36B to $1.46B.
- What is the long-term trend for NewAmsterdam Pharma Company's additional paid-in capital?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's additional paid-in capital has grown at a 36.9% compound annual growth rate (CAGR), from $555.63M to $1.43B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.